A retrospective observation of virologically suppressed people living with HIV by comparing switching to BIC/TAF/FTC with initial use BIC/TAF/FTC

References

• Siripurapu R, Ota Y. Human immunodeficiency virus: opportunistic infections and beyond. Neuroimaging Clin N Am. 2023;33(1):1–7. doi: 10.1016/j.nic.2022.07.014.
   PubMed Web of Science ®Google Scholar
• Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2022;139(7):995–1012. doi: 10.1182/blood.2020005469.
   PubMed Web of Science ®Google Scholar
• Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses. 2011;3(5):586–612. doi: 10.3390/v3050586.
   PubMed Web of Science ®Google Scholar
• Trickey A, May M T, Vehreschild J J ,et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4:e349–e356.DOI:10.1016/S2352-3018(17)30066-8.
   PubMed Web of Science ®Google Scholar
• Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014;3(1):1–17. doi: 10.1007/s40121-014-0024-z.
   PubMedGoogle Scholar
• Ryom L, De Miguel R, Cotter AG, et al. Major revision version 11.0 of the European AIDS Clinical Society guidelines 2021. HIV Med. 2022;23(8):849–858. doi: 10.1111/hiv.13268.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273–1281. doi: 10.1097/QAD.0b013e3280b07b33.
   PubMed Web of Science ®Google Scholar
• Mbuagbaw L, Mursleen S, Irlam JH, et al. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2016;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4.
   PubMedGoogle Scholar
• Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006;20(8):542–548. doi: 10.1089/apc.2006.20.542.
   PubMed Web of Science ®Google Scholar
• Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international Antiviral Society-USA panel. Jama. 2020;324(16):1651–1669. doi: 10.1001/jama.2020.17025.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6(6):e364–e372. doi: 10.1016/S2352-3018(19)30080-3.
   PubMed Web of Science ®Google Scholar
• Daar ES, DeJesus E, Ruane P, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2018;5(7):e347–e356. doi: 10.1016/S2352-3018(18)30091-2.
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Trunfio M, Putaggio C, et al. Viro-Immunological, clinical outcomes and costs of switching to BIC/TAF/FTC in a cohort of people living with HIV: a 48-week prospective analysis. Biomedicines. 2022;10(8):10. doi: 10.3390/biomedicines10081823.
   Web of Science ®Google Scholar
• Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485–e493. doi: 10.1093/cid/ciaa988.
   PubMed Web of Science ®Google Scholar
• Chang HM, Chou PY, Chou CH, et al. Outcomes after switching to BIC/FTC/TAF in patients with virological failure to protease inhibitors or non-nucleoside reverse transcriptase inhibitors: a real-world cohort study. Infect Drug Resist. 2021;14:4877–4886. doi: 10.2147/IDR.S331647.
   PubMed Web of Science ®Google Scholar
• Săndulescu O, Irimia M, Benea OE, et al. Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania. Germs. 2021;11(4):512–522. doi: 10.18683/germs.2021.1286.
   PubMedGoogle Scholar
• Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards sustainable development goal 3. Lancet. 2020;396(10252):693–724. doi: 10.1016/S0140-6736(20)30608-5.
   PubMed Web of Science ®Google Scholar
• Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072. doi: 10.1016/S0140-6736(17)32299-7.
   PubMed Web of Science ®Google Scholar
• Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral Society-USA panel. Jama. 2018;320(4):379–396. doi: 10.1001/jama.2018.8431.
   PubMed Web of Science ®Google Scholar
• Sax PE, Arribas JR, Orkin C, et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023;59:101991. doi: 10.1016/j.eclinm.2023.101991.
   PubMedGoogle Scholar
• Mounzer K, Brunet L, Fusco JS, et al. Advanced HIV infection in treatment-Naïve individuals: effectiveness and persistence of recommended 3-drug regimens. Open Forum Infect Dis. 2022;9(3):ofac018.
   PubMed Web of Science ®Google Scholar
• The IeDEA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis. 2018;66(6):893–903. doi: 10.1093/cid/cix915.
   PubMed Web of Science ®Google Scholar
• Mounzer K, Brunet L, Fusco JS, et al. Immune response to ART initiation in advanced HIV infection. HIV Med. 2023;24(6):716–726. doi: 10.1111/hiv.13467.
   PubMed Web of Science ®Google Scholar
• Koethe JR, Lagathu C, Lake JE, et al. HIV and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6(1):48. doi: 10.1038/s41572-020-0181-1.
   PubMed Web of Science ®Google Scholar
• Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379–1389. doi: 10.1093/cid/ciz999.
   PubMed Web of Science ®Google Scholar
• Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-Based antiretroviral therapy. Clin Infect Dis. 2020;71(9):e471–e477. doi: 10.1093/cid/ciaa177.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33(9):1455–1465. doi: 10.1097/QAD.0000000000002223.
   PubMed Web of Science ®Google Scholar
• Ambrosioni J, Rojas Liévano J, Berrocal L, et al. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77(4):1133–1139. doi: 10.1093/jac/dkab481.
   PubMed Web of Science ®Google Scholar
• Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):576–583. doi: 10.1182/asheducation-2018.1.576.
   PubMedGoogle Scholar